Market Overview

Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab in People with CLL


Emergent BioSolutions (NYSE: EBS) today announced preliminary
results from a Phase 1b single-arm, open-label study evaluating the
safety and efficacy of otlertuzumab (TRU-016) in combination with
rituximab in people with previously untreated chronic lymphocytic
leukemia (CLL) (Study 16009). Data from the first cohort to have
completed enrollment, presented during the American Society of
Hematology annual meeting, showed that the combination was active and
well tolerated.

Otlertuzumab is a humanized anti-CD37 monospecific protein therapeutic,
built on Emergent's ADAPTIRTM (modular protein technology)
platform, that targets the CD37 signaling pathway involved in B-cell
malignancies such as CLL, non-Hodgkin's lymphoma (NHL), diffuse large
B-cell lymphoma (DLBCL) and other cancers of the blood.

See full press release

Posted-In: News Guidance Management Global


Related Articles (EBS)

View Comments and Join the Discussion!